Concepedia

J. Zimmermann

JZ

Statistics

Publications

31

Citations

7.6K

H-Index

27

Active since

1986

Affiliations

Novartis (Switzerland)(Current)

Scripps Research Institute

University of Alberta

ETH Zurich

Brigham and Women's Hospital

J. Zimmermann is an author at Novartis (Switzerland) specializing in medicinal chemistry, chemistry, and pharmacy.

Publications per year

1986–2007

31

Publications

31

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

, , +13

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al. · PubMed · 1996 · 1.1K citations

, , +17

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Martin Carroll, Sayuri Ohno-Jones, Shu Tamura et al. · Blood · 1997 · 520 citations

, , +15

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins

Martin Carroll, Sayuri Ohno-Jones, Shu Tamura et al. · Blood · 1997 · 448 citations · Full text

, , +15

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.

Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al. · Proceedings of the National Academy of Sciences · 1995 · 269 citations · Full text

, , +14

1–5 of 31